Log In
Print
BCIQ
Print
Print this Print this
 

Truvada, emtricitabine/tenofovir

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination of the nucleoside analog reverse transcriptase inhibitors (NRTI) emtricitabine and tenofovir
Molecular Target HIV reverse transcriptase
Mechanism of ActionHIV reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsPre-exposure prophylaxis (PrEP) to reduce risk of HIV-1 infection in uninfected adults; Pre-exposure prophylaxis (PrEP) to reduce risk of HIV-1 infection in uninfected adults in combination with safer sex practices; Prevent HIV infection; Prevent HIV infection in women; Treat HIV infection; Treat HIV infection/AIDS in antiretroviral-naïve patients
Regulatory Designation

Partner

Bristol-Myers Squibb Co.; Mylan Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today